Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome
Authors:
- 1 February 2020
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 156 (2) , 196-200
Abstract
Importance Olmsted syndrome is a rare and disabling genodermatosis for which no successful treatment is currently available. Objective To evaluate the clinical response to the mammalian target of rapamycin (mTOR) inhibitor sirolimus and/or the epidermal growth factor receptor (EGFR) inhibitor erlotinib among patients with Olmsted syndrome. Design, Setting, and Participants This case series focused on 4 children with treatment-refractory Olmsted syndrome. These children received treatments (initiated in 2017 and 2018) at the outpatient dermatology clinic at the Children’s Hospital of Wisconsin in Milwaukee, Wisconsin; Children’s National Hospital in Washington, DC; and Hospital Infantil Pequeno Príncipe, Curitiba in Paraná, Brazil. Exposures Immunohistochemical analyses for mTOR and EGFR activation were performed on skin biopsy specimens from 2 patients. Oral sirolimus was administered to these 2 patients at a dosage of 0.8 mg/m2twice daily, titrated to a goal trough whole-blood concentration of 10 to 15 ng/mL. Erlotinib was administered to all 4 patients at a dosage of 2 mg/kg/d. Main Outcomes and Measures Clinical responses were assessed with visual analog scales for pruritus and pain and/or the Children’s Dermatology Life Quality Index. Adverse effects were monitored throughout treatment. Results Four patients (mean [SD] age, 7 [6] years; 2 boys and 2 girls) were analyzed. Lesional skin immunostaining showed increased phosphorylated ribosomal protein S6 (RPS6) and phosphorylated EGFR staining in the epidermis, indicating enhanced mTOR and EGFR signaling activation. Patients 1 and 2 were initially treated with sirolimus, displaying substantial clinical improvement in erythema and periorificial hyperkeratosis afterward. When switched to erlotinib, these patients showed substantial palmoplantar keratoderma (PPK) improvement. Patients 3 and 4 were treated with erlotinib only and later showed rapid and near complete resolution of PPK and substantial improvement in Children’s Dermatology Life Quality Index scores. All 4 patients had sustained improvements in pruritus and pain. No severe adverse effects were reported. Conclusions and Relevance This study’s findings suggest that the EGFR-mTOR cascade may play a substantial role in the pathophysiological process of Olmsted syndrome and may serve as a major therapeutic target. Oral sirolimus and erlotinib may be a promising, life-altering treatment for pediatric patients with Olmsted syndrome.Keywords
This publication has 15 references indexed in Scilit:
- Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatologyJournal of the American Academy of Dermatology, 2015
- Olmsted syndrome: clinical, molecular and therapeutic aspectsOrphanet Journal of Rare Diseases, 2015
- Ribosomal protein S6 is hyperactivated and differentially phosphorylated in epidermal lesions of patients with psoriasis and atopic dermatitisBritish Journal of Dermatology, 2014
- Exome Sequencing Reveals Mutations in TRPV3 as a Cause of Olmsted SyndromeThe American Journal of Human Genetics, 2012
- Epidermal growth factor receptor inhibition with erlotinib for palmoplantar keratodermaJournal of the American Academy of Dermatology, 2010
- Preventing a Perm with TRPV3Cell, 2010
- TRP Channel Regulates EGFR Signaling in Hair Morphogenesis and Skin Barrier FormationCell, 2010
- Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patientsJournal of Dermatological Science, 2009
- Impact of the Gly573Ser Substitution in TRPV3 on the Development of Allergic and Pruritic Dermatitis in MiceJournal of Investigative Dermatology, 2009
- Beyond Wavy HairsThe American Journal of Pathology, 2008